• Explore /
  • Poster
  • / Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.

Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.

Abstract Poster

Authors

null

Elias Jabbour

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Elias Jabbour , Giovanni Martinelli , Marco Vignetti , Josep-Maria Ribera , David Gomez-Almaguer , Yosuke Minami , Jing Xu , Shouryadeep Srivastava , Frank Neumann , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03589326

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS7061)

DOI

10.1200/JCO.2019.37.15_suppl.TPS7061

Abstract #

TPS7061

Poster Bd #

436a

Abstract Disclosures

Similar Posters

First Author: Koji Sasaki

First Author: Jeffrey Howard Lipton

First Author: Jeffrey H. Lipton

First Author: Jeremy Chang